Pasar al contenido principal

TERAPIAS BASADAS EN GLICOMIMETICOS PARA EL TRATAMIENTO DE ENFERMEDADES DE PLEGAMIENTO DE PROTEINAS, INFLAMACION Y CANCER.

BES-2017-079676

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Potent and Selective Cell-Active Iminosugar Inhibitors of Human α-N-Acetylgalactosaminidase (α-NAGAL)

  • Ashmus, Roger A.
  • Wang, Yang
  • González-Cuesta, Manuel
  • King, Dustin T
  • Tiet, Ben
  • Chen, Xi
  • Zhu, Yanping
  • Kirk, Bryce
  • García Fernández, José Manuel
  • Ortiz-Mellet, Carmen
  • Britton, Robert
  • Vocadlo, David J
Glycoside hydrolases (GHs) are a class of enzymes with emerging roles in a range of disease. Selective GH inhibitors are sought to better understand their functions and assess the therapeutic potential of modulating their activities. Iminosugars are a promising class of GH inhibitors but typically lack the selectivity required to accurately perturb biological systems. Here, we describe a concise synthesis of iminosugar inhibitors of N-acetyl-α-galactosaminidase (α-NAGAL), the GH responsible for cleaving terminal α-N-acetylgalactosamine residues from glycoproteins and other glycoconjugates. Starting from non-carbohydrate precursors, this modular synthesis supported the identification of a potent (490 nM) and α-NAGAL selective (∼200-fold) guanidino-containing derivative DGJNGuan. To illustrate the cellular activity of this new inhibitor, we developed a quantitative fluorescence image-based method to measure levels of the Tn-antigen, a cellular glycoprotein substrate of α-NAGAL. Using this assay, we show that DGJNGuan exhibits excellent inhibition of α-NAGAL within cells using patient derived fibroblasts (EC50 =150 nM). Moreover, in vitro and in cell assays to assess levels of lysosomal β-hexosaminidase substrate ganglioside GM2 show that DGJNGuan is selective whereas DGJNAc exhibits off-target inhibition both in vitro and within cells. DGJNGuan is a readily produced and selective tool compound that should prove useful for investigating the physiological roles of α-NAGAL., The authors thank the Natural Sciences and Engineering Research Council of Canada (RGPIN-2020-05426 to DJV), AEI/10.13039/501100011033 (PID2019-105858RB-I00 to COM), MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (PID2021-124247OB-C21 to JMGF), and the Junta de Andalucía (P20_00166 and US-1380698 to COM) for financial support. RAA thanks the Michael Smith Foundation for Health Research for a fellowship. MG-C thanks FPI (BES-2017-079676) and University of Seville for fellowships. DJV thanks the Canada Research Chairs for a Tier I Canada Research Chair in Chemical Biology. The Centre for High-Throughput Chemical Biology (HTCB, SFU) and CITIUS (Univ. Seville) are thanked for technical support and for access to core facilities.Dr. Pierre-Andre Gilormini is thanked for expert assistance with graphics., Peer reviewed